Engineering chimeric antigen receptor-T cells for cancer treatment
Abstract Intratumor heterogeneity of tumor clones and an immunosuppressive microenvironment in cancer ecosystems contribute to inherent difficulties for tumor treatment.Recently, chimeric tennessee vols boots antigen receptor (CAR) T-cell therapy has been successfully applied in the treatment of B-cell malignancies, underscoring its great potential